Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patterns of joint damage in severe haemophilia A treated with prophylaxis.
Goren R, Pullenayegum E, Blanchette VS, Dover S, Carcao M, Israels SJ, Chan A, Rivard GE, Steele M, Cloutier S, Klaassen RJ, Sinha R, Price VE, Laferriere N, Paradis E, Wu JK, Feldman BM. Goren R, et al. Among authors: laferriere n. Haemophilia. 2021 Jul;27(4):666-673. doi: 10.1111/hae.14345. Epub 2021 May 20. Haemophilia. 2021. PMID: 34015166
Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort.
Feldman BM, Rivard GE, Babyn P, Wu JKM, Steele M, Poon MC, Card RT, Israels SJ, Laferriere N, Gill K, Chan AK, Carcao M, Klaassen RJ, Cloutier S, Price VE, Dover S, Blanchette VS. Feldman BM, et al. Among authors: laferriere n. Lancet Haematol. 2018 Jun;5(6):e252-e260. doi: 10.1016/S2352-3026(18)30048-6. Epub 2018 May 3. Lancet Haematol. 2018. PMID: 29731369
Magnetic resonance imaging in boys with severe hemophilia A: Serial and end-of-study findings from the Canadian Hemophilia Primary Prophylaxis Study.
Stimec J, Dover S, Pullenayegum E, Blanchette VS, Doria AS, Feldman BM, Carcao M, Rivard GE, Israels SJ, Chan AK, Steele M, Cloutier S, Klaassen RJ, Price VE, Sinha R, Laferriere N, Paradis E, Wu JKM, Babyn P. Stimec J, et al. Among authors: laferriere n. Res Pract Thromb Haemost. 2021 Oct 16;5(7):e12565. doi: 10.1002/rth2.12565. eCollection 2021 Oct. Res Pract Thromb Haemost. 2021. PMID: 34703973 Free PMC article.
Hemophilia prophylaxis adherence and bleeding using a tailored, frequency-escalated approach: The Canadian Hemophilia Primary Prophylaxis Study.
Dover S, Blanchette VS, Wrathall D, Pullenayegum E, Kazandjian D, Song B, Hawes SA, Cloutier S, Rivard GE, Klaassen RJ, Paradis E, Laferriere N, Stain AM, Chan AK, Israels SJ, Sinha R, Steele M, Wu JKM, Feldman BM. Dover S, et al. Among authors: laferriere n. Res Pract Thromb Haemost. 2020 Jan 29;4(2):318-325. doi: 10.1002/rth2.12301. eCollection 2020 Feb. Res Pract Thromb Haemost. 2020. PMID: 32110763 Free PMC article.
Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study.
Hilliard P, Zourikian N, Blanchette V, Chan A, Elliott B, Israels SJ, Nilson J, Poon MC, Laferriere N, Van Neste C, Jarock C, Wu J, McLimont M, Feldman B. Hilliard P, et al. Among authors: laferriere n. J Thromb Haemost. 2013 Mar;11(3):460-6. doi: 10.1111/jth.12113. J Thromb Haemost. 2013. PMID: 23301594 Free article.
[No title available]
[No authors listed] [No authors listed] PMID: 33704166
Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.
Skamene T, Crump M, Savage KJ, Reiman T, Kuruvilla J, Good D, LeBrun D, Meyer RM, Sehn LH, Soulières D, Stakiw J, Laferriere N, Luminari S, Shepherd LE, Djurfeldt M, Zhu L, Chen BE, Hay AE. Skamene T, et al. Among authors: laferriere n. Leuk Lymphoma. 2017 Oct;58(10):2319-2327. doi: 10.1080/10428194.2017.1312379. Epub 2017 May 15. Leuk Lymphoma. 2017. PMID: 28504033 Clinical Trial.
38 results